Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications

Executive Summary

Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.
Advertisement

Related Content

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA
Serious Candida Infections: Scynexis's Oral Antifungal Could Challenge Fluconazole
Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US
BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy
Pipeline Watch: Phase III Read-Outs For Ozanimod, Olaparib And Sapacitabine
Cidara CEO Stein brings Trius gang, biotech vets together

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100594

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel